Chong joined IMU in September 2015 from the pharmaceutical giant, Genentech, in San Francisco where she had a distinguished career across many aspects of drug development.
Imugene is a clinical stage immuno-oncology company, with its lead product being HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer.
The company is also developing mimotope-based immunotherapies against validated and new oncology targets.